| Filed On | Filing |
|---|---|
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
In-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group transformed Nuvectis into a late-stage clinical development company. |
| 28 Aug 2026 | EFFECT |
| 21 Aug 2026 | FORM S-3 |
| 21 Aug 2026 |
8-K: Other Events
Nuvectis Pharma, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares ... |
| 06 Aug 2026 | SCHEDULE 13G |
| 05 Aug 2026 |
Form 4: Carson Michael J., Vice President, Finance
Received 30,000 shares as a grant or award |
| 04 Aug 2026 | 10-Q |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition
Completed in-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group (“Haisco”), transforming the company into a late-stage clinical development organization. |
| 01 Jul 2026 |
Form 4: Mosseri Marlio Charles, 10% owner
Bought 50,000 shares ($916K) |
| 01 Jul 2026 |
Form 4: Bentsur Ron, Director
Bought 12,500 shares ($250K) |
| 30 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
As Representative of the several Underwriters listed on Schedule IA hereto |
| 30 Jun 2026 | 424B5 |
| 29 Jun 2026 | 424B5 |
| 29 Jun 2026 |
8-K: Other Events
As previously disclosed, on May 9, 2025, Nuvectis Pharma, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (the “Agent”) pursuant to which the Company may sell, from time to time, at i... |
| 23 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds |
| 12 Jun 2026 |
Form 4: Hoberman Kenneth, Director
Received 35,000 shares as a grant or award |
| 12 Jun 2026 |
Form 4: Kaplan Matthew L., Director
Received 35,000 shares as a grant or award |
| 12 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On Thursday, June 11, 2026, at 10:00 a.m. Eastern Time, by means of an online meeting platform, Nuvectis Pharma, Inc. (the “Company”) held its 2026 Annual Meeting (the “Annual Meeting”). |
| 12 Jun 2026 |
Form 4: Oliviero James F Iii, Director
Received 35,000 shares as a grant or award |
Loading...